Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22834639 | 0.90 | — | — | |
| SCHEMBL4474354 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TSHRGLAHSP90AA1HSD11B1 | |
| SCHEMBL25568411 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRGLAHSP90AA1HSD11B1 | |
| SCHEMBL2533725 | 0.76 | ALDH1A1 (0.49) | ALDH1A1TSHRHSP90AA1HSD11B1L3MBTL1 | |
| SCHEMBL1072478 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TSHRGLAHSP90AA1HSD11B1 | |
| SCHEMBL14341893 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRHSP90AA1HSD11B1L3MBTL1 | |
| SCHEMBL11760004 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRHSP90AA1HSD11B1L3MBTL1 | |
| SCHEMBL1075076 | 0.74 | ALDH1A1 (0.49) | ALDH1A1TSHRHSD11B1LMNAKDM4E | |
| SCHEMBL10775431 | 0.74 | ALDH1A1 (0.66) | ALDH1A1TSHRGLAHSP90AA1HSD11B1 | |
| SCHEMBL3322713 | 0.74 | HTT (0.53) | ALDH1A1TSHRGLAHSP90AA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104840975-B | A kind of super-molecule assembling body and preparation method of targeted delivery siRNA | 南开大学 | 2018-01-23 | — | — | CN | claimed |
| US-8703194-B2 | Stimulus-responsive biodegradable polymers and methods of preparation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-04-22 | — | — | US | claimed |
| US-8658209-B2 | — | — | 2014-02-25 | — | — | US | claimed |
| US-20090123544-A1 | STIMULUS-RESPONSIVE BIODEGRADABLE POLYMERS AND METHODS OF PREPARATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2009-05-14 | — | — | US | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| CN-112368640-B | Actinic-ray-or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device | 富士胶片株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-12216404-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2025-02-04 | — | — | US | disclosed |
| WO-2023020486-A1 | RIP1 KINASE INHIBITOR COMPOUND AND COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| US-20210088905-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2021-03-25 | — | — | US | disclosed |
| US-4143127-A | CONTAINING ADAMAMTANE RING | COLGATE PALMOLIVE COMPANY (US) | 1979-03-06 | — | — | US | disclosed |
| US-4123516-A | Quaternary compounds having anti-microbial activity | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4123515-A | Quaternary compounds having anti-microbial activity | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4123514-A | Quaternary compounds having anti-microbial activity | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4123513-A | Quaternary compounds having anti-microbial activity | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4036975-A | FUNGICIDES, BACTERICIDES AND ANTIPROTOZOA AGENTS | XYNTEX (U.S.A) INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-3992431-A | ALSO ANTICARIES AND ANTICALCULUS ACTIVITY | COLGATE-PALMOLIVE COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3961074-A | ANTICARIES AGENTS | COLGATE-PALMOLIVE COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | ALDH1A1 2267/4885TSHR 1512/4885GLA 1424/4885 |
| US-20090123544-A1 | STIMULUS-RESPONSIVE BIODEGRADABLE POLYMERS AND METHODS OF PREPARATION | PAM, ATF4, MYD88 | ALDH1A1 4408/4885TSHR 756/4885GLA 1217/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | ALDH1A1 2267/4885TSHR 1512/4885GLA 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.